086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

Inadequate Response ◽

Phase 3 ◽

Safety And Efficacy ◽

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)31116-4 ◽

2018 ◽

Vol 391 (10139) ◽

pp. 2513-2524 ◽

Cited By ~ 119

Author(s):

Mark C Genovese ◽

Roy Fleischmann ◽

Bernard Combe ◽

Stephen Hall ◽

Andrea Rubbert-Roth ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Disease Modifying ◽

Randomised Controlled

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)31115-2 ◽

2018 ◽

Vol 391 (10139) ◽

pp. 2503-2512 ◽

Cited By ~ 114

Author(s):

Gerd R Burmester ◽

Joel M Kremer ◽

Filip Van den Bosch ◽

Alan Kivitz ◽

Louis Bessette ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice

Clinical Rheumatology ◽

10.1007/s10067-019-04815-8 ◽

2019 ◽

Vol 39 (5) ◽

pp. 1449-1455

Author(s):

Elyes Bouajina ◽

Leith Zakraoui ◽

Montassar Kchir ◽

Samir Kochbati ◽

Sofiene Baklouti

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Practice ◽

Inadequate Response ◽

Safety And Efficacy ◽

Tunisian Patients ◽

FRI0154 SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)

10.1136/annrheumdis-2019-eular.2121 ◽

2019 ◽

Author(s):

Kenneth Kalunian ◽

Jacques-Eric Gottenberg ◽

Mark C. Genovese ◽

Neelufar Mozaffarian ◽

Beatrix Bartok ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Safety And Efficacy ◽

Biological Dmards

AB0448 SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS

10.1136/annrheumdis-2019-eular.2123 ◽

2019 ◽

Author(s):

Tsutomu Takeuchi ◽

Tsukasa Matsubara ◽

Tatsuya Atsumi ◽

Koichi Amano ◽

Naoki Ishiguro ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Japanese Patients ◽

Inadequate Response ◽

Phase 3 ◽

Biologic Dmards ◽

Safety And Efficacy

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.1239 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 412.2-413 ◽

Cited By ~ 1

Author(s):

E. Keystone ◽

P. Taylor ◽

Y. Tanaka ◽

C. Gaich ◽

A.M. DeLozier ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Patient Reported Outcomes ◽

Methotrexate Therapy ◽

Inadequate Response ◽

Phase 3 ◽

Patient Reported

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease‑modifying anti‑rheumatic drugs: A meta‑analysis of randomized controlled trials

Experimental and Therapeutic Medicine ◽

10.3892/etm.2018.6495 ◽

2018 ◽

Cited By ~ 2

Author(s):

Zhi‑Peng Wu ◽

Pei Zhang ◽

Jian‑Zhong Bai ◽

Yuan Liang ◽

Jin‑Shan He ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Controlled Trials ◽

Inadequate Response ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Effectiveness and Safety of Tacrolimus in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-modifying Anti-rheumatic Drugs: The TREASURE Study

Journal of Rheumatic Diseases ◽

10.4078/jrd.2019.26.1.20 ◽

2019 ◽

Vol 26 (1) ◽

pp. 20

Author(s):

Dong Hyuk Sheen ◽

Seung Jae Hong ◽

Sang Heon Lee ◽

Hye Soon Lee ◽

Won Tae Chung ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.730 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A232.1-A232 ◽

Cited By ~ 2

Author(s):

J. S. Smolen ◽

J. Kay ◽

R. Landewé ◽

E. L. Matteson ◽

N. Gaylis ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase 3 ◽

Safety And Efficacy ◽

Final Study ◽

Study Results ◽

Factor Therapy ◽

Necrosis Factor

SAT0219 Upadacitinib in patients with active rheumatoid arthritis and inadequate response or intolerance to biological dmards: a phase 3 randomized, placebo-controlled, double-blind study of a selective jak1 inhibitor

10.1136/annrheumdis-2018-eular.4180 ◽

2018 ◽

Author(s):

M. C. Genovese ◽

R. Fleischmann ◽

B. Combe ◽

S. Hall ◽

Y. Zhang ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Blind Study ◽

Double Blind Study ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Biological Dmards